CSIMarket
 
Indaptus Therapeutics Inc   (INDP)
Other Ticker:  
 
 
Price: $1.8700 $-0.04 -2.094%
Day's High: $2.01 Week Perf: -7.43 %
Day's Low: $ 1.87 30 Day Perf: 11.31 %
Volume (M): 30 52 Wk High: $ 4.08
Volume (M$): $ 56 52 Wk Avg: $2.14
Open: $1.91 52 Wk Low: $1.53



 Market Capitalization (Millions $) 16
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Indaptus Therapeutics Inc
Indaptus Therapeutics Inc is a pharmaceutical company that focuses on developing innovative therapies for the treatment of various diseases. The company's main area of expertise lies in the field of gene therapy and genetic medicine.

Indaptus Therapeutics Inc utilizes cutting-edge technology and research to identify and develop gene therapies that target specific genetic mutations and diseases. This approach holds great potential for the treatment of genetic disorders that currently have limited or no treatment options.

The company's goal is to bring forward transformative therapies that can improve patient outcomes and quality of life. Indaptus Therapeutics Inc collaborates with leading academic institutions and research organizations to advance its pipeline of therapeutics.

With a strong focus on precision medicine, Indaptus Therapeutics Inc aims to develop personalized therapies that are tailored to individual patients' genetic profiles. This approach has the potential to revolutionize the way diseases are treated by addressing the underlying genetic causes.

Overall, Indaptus Therapeutics Inc is dedicated to pushing the boundaries of medicine and making a lasting impact in the field of gene therapy, with the ultimate objective of improving the lives of patients suffering from genetic diseases.


   Company Address: 3 Columbus Circle New York 10019 NY
   Company Phone Number: 427-2727   Stock Exchange / Ticker: NASDAQ INDP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Promising Results from Indaptus Therapeutics' Phase 1 Trial Propel Advancements in Multi-Dosing Cohort

Published Mon, Mar 4 2024 12:30 PM UTC

Indaptus Therapeutics, a leading biopharmaceutical company, has revealed encouraging results from the completion of the second cohort in their Phase 1 clinical trial for the investigational drug, Decoy 20. The positive data obtained has prompted the independent Safety Review Committee to recommend the initiation of a multi-dosing cohort. This significant development undersco...

Indaptus Therapeutics Inc

Indaptus Therapeutics Inc Triumphs Over Q2 Challenges, Reducing Operating Shortfall to $-3.8M

The Major Pharmaceutical Preparations industry has been closely monitored by reporters who are now analyzing the performance of the second quarter of 2023. One notable observation is the operating shortfall of $-3.495262 million reported by Indaptus Therapeutics Inc. However, what makes this news particularly encouraging is the fact that the company has not yet mentioned any revenue for the April to June 30, 2023 quarter. Despite the lack of revenue information, the improvement from the operating shortfall of $-3.86926 million in the second quarter of 2022 is generating optimism among analysts.
Furthermore, the deficit has declined from $-3.836 million in the second quarter of 2022 to $-3.245 million in the same time frame in 2023. This decline may prove beneficial to Indaptus Therapeutics Inc. as it strives to establish itself as a standout leader in the pharmaceutical industry. These developments indicate progress in the company's journey towards financial stability and growth.

Indaptus Therapeutics Inc

Indaptus Therapeutics Inc Takes Bold Steps Towards Financial Success in Q1 2023 Earnings Season

Indaptus Therapeutics Inc - Rebounding Strong for a Promising Future!
Pharmaceutical companies play a vital role in the healthcare industry by discovering and developing new therapies to improve patient outcomes. As the January to March 31, 2023, reporting cycle unfolds, we have seen various entities from the Major Pharmaceutical Preparations sector release their numbers. Among these entities, Indaptus Therapeutics Inc has recently reported its earnings for Q1 2023.
Despite experiencing an operating shortfall of $-4.455166 million for the first quarter of this year, Indaptus Therapeutics has shown a remarkable improvement from the previous year. In Q1 2021, the operating shortfall was $-3.367991 million, indicating that the company's management has been proactively addressing financial issues. Furthermore, Indaptus incurred a net deficit of $-4.253 million, which was an extension from $-3.367 million in the same timeframe a year prior.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com